Fig. 6

Anti-tumor activity of SKF83566 targets the DRD1-cMyc-UHRF1 axis in vitro and in vivo. (A) Quantitative RT-PCR for c-Myc in P3 and BG5 human GSCs transfected with si-NC, si-DRD1-2 or si-DRD1-3. Data are shown as the mean ± SEM. Statistical significance was determined by ANOVA. ***P < 0.001. (B) Western blots to detect c-Myc and UHRF1 in P3 and BG5-DRD1-OE human GSCs (overexpression of DRD1) treated with SKF83566. (C and D) Bioluminescence images and the corresponding quantification of tumor burden in mice implanted with BG5-sh-NC or -sh-DRD1 human GSCs at days 30, 44, and 84. (n = 5 per group). Data are shown as mean ± SEM. Statistical significance was determined by ANOVA. **P < 0.01. (E) Representative hematoxylin and eosin staining of mouse brains implanted with BG5-sh-DRD1/sh-NC cells. Scale bar = 2.5 mm (Left) and 500 μm (Right). (F) The survival curves of tumor-bearing mice implanted with BG5-sh-DRD1/sh-NC cells (n = 5 per group). A log-rank test was used to assess statistical significance. Data are shown as mean ± SEM. **P < 0.05. (G) Quantification of immunohistochemistry for c-Myc, UHRF1, and Ki67 in sections from BG5-sh-DRD1/sh-DRD1-NC xenografts. Data are shown as the mean ± SEM. Statistical significance was determined by unpaired Student’s t-test. ***P < 0.001. (H) Schematic diagram of SKF83566 targeting the DRD1-c-Myc-UHRF1 axis inhibiting GSC invasion and stemness